-
2025-12-23
GenSci Partners with Leading AI Company Partex AI to Accelerate Drug Development and Global CommercializationLearn More
-
2025-12-16
GenSci Secures Up to $1.365B in Global ex-China Licensing Deal for GS-098(YB-101) with RTW InvestmentsLearn More
-
2025-12-02
A Leading Force in Innovation:
GenSci Earns Dual Recognition as Global Innovator & 2025 China Pharma Top 100Learn More
-
2025-09-18
GenSci Partners with Allergy Immunotherapy Leader ALK to Bring Innovative AIT Solutions for Chinese PatientsLearn More
-
2025-07-04
Firsekibart Approved with 87% Reduction in Gout Recurrence Over 6 MonthsLearn More
-
2025-06-18
NMPA Approves New Indication Clinical Trial of Megestrol Acetate Oral SuspensionLearn More
-
2025-06-17
Gensci Showcases BsADC Pipeline at 4th World ADC Asia SummitLearn More
-
2025-05-30
The FDA has Cleared the IND Application for GenSci128 for TP53 Y220C-Mutated Solid TumorsLearn More
-
2025-05-20
GenSci 2025 R&D Day: The Next Growth Frontier for a Billion-Dollar Growth Hormone LeaderLearn More
-
2025-03-21
Global R&D Milestone: Clinical Trial of GenSci120 Will Be Launched in the U.S.Learn More
-
2025-03-07
Episil® Launched in China: A Breakthrough Solution for Oral MucositisLearn More
-
2025-02-20
GenSci Submits Another Blockbuster Product for Market ApprovalLearn More